S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:LUNG

Pulmonx (LUNG) Stock Forecast, Price & News

$12.75
+0.32 (+2.57%)
(As of 06/6/2023 ET)
Compare
Today's Range
$12.38
$13.14
50-Day Range
$10.78
$13.13
52-Week Range
$4.07
$24.49
Volume
298,293 shs
Average Volume
429,405 shs
Market Capitalization
$481.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75

Pulmonx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
15.7% Upside
$14.75 Price Target
Short Interest
Bearish
8.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Pulmonx in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$199,519 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.70) to ($1.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

817th out of 981 stocks

Surgical & Medical Instruments Industry

78th out of 97 stocks


LUNG stock logo

About Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

LUNG Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Pulmonx (NASDAQ:LUNG) Announces Quarterly Earnings Results
7 Analysts Have This to Say About Pulmonx
A Preview Of Pulmonx's Earnings
Pulmonx (LUNG) to Release Quarterly Earnings on Tuesday
Analysts Set Pulmonx Co. (NASDAQ:LUNG) PT at $14.50
Pulmonx Stock (NASDAQ:LUNG), Dividends
Citigroup Raises Pulmonx (NASDAQ:LUNG) Price Target to $13.00
See More Headlines

LUNG Price History

LUNG Company Calendar

Last Earnings
5/02/2023
Today
6/06/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUNG
Fax
N/A
Employees
253
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.75
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+15.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-58,920,000.00
Net Margins
-102.69%
Pretax Margin
-101.97%

Debt

Sales & Book Value

Annual Sales
$53.66 million
Book Value
$4.12 per share

Miscellaneous

Free Float
35,596,000
Market Cap
$481.31 million
Optionable
Not Optionable
Beta
0.32

Key Executives

  • Mr. Glendon E. FrenchMr. Glendon E. French (Age 61)
    CEO, Pres & Director
    Comp: $899.58k
  • Mr. David A. LehmanMr. David A. Lehman (Age 62)
    Gen. Counsel & Sec.
    Comp: $569.14k
  • Mr. Geoffrey Beran RoseMr. Geoffrey Beran Rose (Age 50)
    Chief Commercial Officer
    Comp: $524.99k
  • Dr. Derrick Sung Ph.D. (Age 50)
    Chief Financial Officer
  • Mr. Sri Radhakrishnan
    Chief Technical Officer
  • Ms. Lauren Cristina
    VP of Fin. & Admin. (U.S.)
  • Ms. Marcee M. Maroney (Age 53)
    VP of Marketing
  • Sarah Huber
    VP of Sales (U.S.)
  • Ms. Lisa Paul (Age 59)
    Chief People Officer
  • Mr. Jérôme Erath
    Sr. VP & GM of Europe Middle-East & Africa













LUNG Stock - Frequently Asked Questions

Should I buy or sell Pulmonx stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUNG shares.
View LUNG analyst ratings
or view top-rated stocks.

What is Pulmonx's stock price forecast for 2023?

7 brokers have issued 1 year target prices for Pulmonx's stock. Their LUNG share price forecasts range from $8.00 to $20.00. On average, they predict the company's stock price to reach $14.75 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price.
View analysts price targets for LUNG
or view top-rated stocks among Wall Street analysts.

How have LUNG shares performed in 2023?

Pulmonx's stock was trading at $8.43 at the beginning of the year. Since then, LUNG stock has increased by 51.2% and is now trading at $12.75.
View the best growth stocks for 2023 here
.

When is Pulmonx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our LUNG earnings forecast
.

How were Pulmonx's earnings last quarter?

Pulmonx Co. (NASDAQ:LUNG) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.01. The company earned $14.50 million during the quarter, compared to analysts' expectations of $13.49 million. Pulmonx had a negative trailing twelve-month return on equity of 37.22% and a negative net margin of 102.69%. The company's revenue was up 34.3% on a year-over-year basis. During the same period last year, the company posted ($0.43) earnings per share.

What ETFs hold Pulmonx's stock?
What guidance has Pulmonx issued on next quarter's earnings?

Pulmonx updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63.00 million-$65.00 million, compared to the consensus revenue estimate of $64.44 million.

When did Pulmonx IPO?

(LUNG) raised $100 million in an initial public offering (IPO) on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Pulmonx's stock symbol?

Pulmonx trades on the NASDAQ under the ticker symbol "LUNG."

Who are Pulmonx's major shareholders?

Pulmonx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.17%), Braidwell LP (3.08%), FMR LLC (2.55%), State Street Corp (2.51%), Geode Capital Management LLC (1.85%) and Deutsche Bank AG (1.44%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, Richard Ferrari and Scientific Corp Boston.
View institutional ownership trends
.

How do I buy shares of Pulmonx?

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmonx's stock price today?

One share of LUNG stock can currently be purchased for approximately $12.75.

How much money does Pulmonx make?

Pulmonx (NASDAQ:LUNG) has a market capitalization of $481.31 million and generates $53.66 million in revenue each year. The company earns $-58,920,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

How many employees does Pulmonx have?

The company employs 253 workers across the globe.

How can I contact Pulmonx?

The official website for the company is pulmonx.com. The company can be reached via phone at 1-650-364-0400 or via email at investors@pulmonx.com.

This page (NASDAQ:LUNG) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -